The estimated Net Worth of Jeffrey A Munsie is at least 909 千$ dollars as of 15 February 2023. Mr. Munsie owns over 3,762 units of Concert Pharmaceuticals Inc stock worth over 736,970$ and over the last 7 years he sold CNCE stock worth over 171,696$. In addition, he makes 0$ as Chief Legal Officer、 Secretary at Concert Pharmaceuticals Inc.
Jeffrey has made over 6 trades of the Concert Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,762 units of CNCE stock worth 31,375$ on 15 February 2023.
The largest trade he's ever made was selling 8,493 units of Concert Pharmaceuticals Inc stock on 30 January 2023 worth over 70,917$. On average, Jeffrey trades about 1,598 units every 46 days since 2017. As of 15 February 2023 he still owns at least 88,049 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Mr. Munsie stock trades at the bottom of the page.
Jeffrey A. Munsie serves as Chief Legal Officer, Secretary of the Company. Mr. Munsie has served as our Chief Legal Officer and Secretary since September 2019. Prior to joining Concert, Mr. Munsie served as General Counsel, Head of Corporate Operations and Secretary at Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, until July 2019. Mr. Munsie joined Merrimack in February 2011 and became Secretary in August 2011, General Counsel in January 2013 and Head of Corporate Operations in March 2017. Previously, Mr. Munsie was Counsel in the corporate department at Wilmer Cutler Pickering Hale and Dorr LLP, a law firm, where he practiced from 2002 to January 2011. Mr. Munsie received an A.B from Dartmouth College and a J.D. from Harvard Law School.
Jeffrey Munsie is 42, he's been the Chief Legal Officer、 Secretary of Concert Pharmaceuticals Inc since 2019. There are 15 older and no younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over 69,766,120$ worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth 25,219,472$ . The most active insiders traders include Plc Gsk、Associates Gp Llcqvt Fund V...、Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of 447,820$. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth 50,380$.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: